Published in Neuropsychopharmacology on July 03, 2013
3D in vitro modeling of the central nervous system. Prog Neurobiol (2014) 0.93
The proteome of schizophrenia. NPJ Schizophr (2015) 0.79
Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. Mol Autism (2014) 0.78
Psychiatric disorders biochemical pathways unraveled by human brain proteomics. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacology (Berl) (2015) 0.75
Engineered 3D Silk-collagen-based Model of Polarized Neural Tissue. J Vis Exp (2015) 0.75
Combined Metabolomics and Proteomics Analysis of Major Depression in an Animal Model: Perturbed Energy Metabolism in the Chronic Mild Stressed Rat Cerebellum. OMICS (2015) 0.75
Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett (2004) 11.00
Decoding of cytosolic calcium oscillations in the mitochondria. Cell (1995) 7.31
Neuronal calcium signaling. Neuron (1998) 7.03
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev (1990) 5.94
Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature (1994) 5.17
Regulation of mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic priming. Proc Natl Acad Sci U S A (1999) 4.40
The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem (2002) 4.20
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry (2004) 3.90
Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron (1999) 3.36
Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res (2008) 2.67
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62
Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology (1995) 2.53
Microarray reality checks in the context of a complex disease. Nat Biotechnol (2004) 2.51
Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci (2012) 1.80
Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci (2002) 1.79
Physiological role of mitochondrial Ca2+ transport. J Bioenerg Biomembr (1994) 1.77
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry (1995) 1.71
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther (2010) 1.57
Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A (2003) 1.54
Calcium signalling remodelling and disease. Biochem Soc Trans (2012) 1.40
Molecular mechanisms of CaMKII activation in neuronal plasticity. Curr Opin Neurobiol (2002) 1.37
Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res (2005) 1.35
Potential metabolite markers of schizophrenia. Mol Psychiatry (2011) 1.35
A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry (2006) 1.31
The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem (2002) 1.31
Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry (2008) 1.28
Expression of the neuronal calcium sensor protein family in the rat brain. Neuroscience (2000) 1.27
Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int (2007) 1.24
Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry (2008) 1.24
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
Neuronal Ca2+/calmodulin-dependent protein kinase II--discovery, progress in a quarter of a century, and perspective: implication for learning and memory. Biol Pharm Bull (2005) 1.19
Glucose is necessary to maintain neurotransmitter homeostasis during synaptic activity in cultured glutamatergic neurons. J Cereb Blood Flow Metab (2006) 1.18
Altered gene expression in the superior temporal gyrus in schizophrenia. BMC Genomics (2008) 1.17
Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol (2007) 1.17
The darker side of Ca2+ signaling by neuronal Ca2+-sensor proteins: from Alzheimer's disease to cancer. Trends Pharmacol Sci (2005) 1.16
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry (2006) 1.09
Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2007) 1.09
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry (2004) 1.08
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res (2010) 1.06
Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol (1992) 1.06
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci (2001) 1.06
Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry (2009) 1.04
Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem (2012) 1.03
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol (2005) 1.03
Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse (2006) 1.02
Schizophrenia and HLA: a review. Schizophr Res (2001) 1.01
Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol (2000) 1.01
More evidence supports the association of PPP3CC with schizophrenia. Mol Psychiatry (2007) 1.01
State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry (2002) 1.01
Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. Biol Psychiatry (2005) 0.97
Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons. J Neurosci Res (2001) 0.97
Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am J Psychiatry (2004) 0.95
Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry (2011) 0.95
Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol (1979) 0.94
The role of calcium signaling in early axonal and dendritic morphogenesis of rat cerebral cortex neurons under non-stimulated growth conditions. Brain Res Dev Brain Res (2001) 0.93
Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport (2001) 0.92
Cytosolic Ca2+ regulates the energization of isolated brain mitochondria by formation of pyruvate through the malate-aspartate shuttle. Biochem J (2012) 0.91
The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples. BMC Med Genet (2008) 0.91
Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol Psychiatry (2010) 0.90
Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res (2009) 0.90
A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry (2008) 0.88
Hippocampal expression of the calcium sensor protein visinin-like protein-1 in schizophrenia. Neuroreport (2002) 0.86
Genome-widely significant evidence of linkage of schizophrenia to chromosomes 2p24.3 and 6q27 in an SNP-Based analysis of Korean families. Am J Med Genet B Neuropsychiatr Genet (2009) 0.85
Association of VSNL1 with schizophrenia, frontal cortical function, and biological significance for its gene product as a modulator of cAMP levels and neuronal morphology. Transl Psychiatry (2011) 0.85
Brain region-specific changes in the expression of calcium sensor proteins after repeated applications of ketamine to rats. Neurosci Lett (2003) 0.84
Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behav Brain Res (2007) 0.84
Molecular validation of the acute phencyclidine rat model for schizophrenia: identification of translational changes in energy metabolism and neurotransmission. J Proteome Res (2012) 0.83
Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry (2012) 0.82
Mitochondrial Ca(2+) as a key regulator of mitochondrial activities. Adv Exp Med Biol (2012) 0.81
NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: a synaptic proteome study. Schizophr Bull (2010) 0.81
Reciprocal regulation between taurine and glutamate response via Ca2+-dependent pathways in retinal third-order neurons. J Biomed Sci (2010) 0.80
The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res (2009) 0.80
Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7 T proton magnetic resonance spectroscopy. Neurochem Int (2012) 0.80
An organelle proteomic method to study neurotransmission-related proteins, applied to a neurodevelopmental model of schizophrenia. Proteomics (2007) 0.79
Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders. Int Rev Neurobiol (2011) 0.79
Schizophrenia: elevated mRNA for calcium-calmodulin-dependent protein kinase IIbeta in frontal cortex. Brain Res Mol Brain Res (2000) 0.79
Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport (1993) 0.79
Divalent cations and redox conditions regulate the molecular structure and function of visinin-like protein-1. PLoS One (2011) 0.78
Increase in [3H]cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res (1993) 0.77
Schizophrenia-like syndrome inducing agent phencyclidine failed to impair memory for temporal order in rats. Neurobiol Learn Mem (2003) 0.76
Host-gut microbiota metabolic interactions. Science (2012) 7.73
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol (2005) 5.35
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem (2005) 4.14
Chemometrics in metabonomics. J Proteome Res (2007) 4.02
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol (2007) 3.68
Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut (2011) 3.42
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Multiple parasite infections and their relationship to self-reported morbidity in a community of rural Côte d'Ivoire. Int J Epidemiol (2004) 2.84
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A (2010) 2.52
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol (2008) 2.17
NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed (2005) 2.15
Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A (2004) 2.11
Metabolic phenotyping in clinical and surgical environments. Nature (2012) 2.09
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
The challenges of modeling mammalian biocomplexity. Nat Biotechnol (2004) 2.03
Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal Chem (2011) 2.02
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res (2007) 1.99
Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res (2006) 1.96
Metabonomics in pharmaceutical R&D. FEBS J (2007) 1.93
Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem (2004) 1.88
The human gut microbiome: implications for future health care. Curr Gastroenterol Rep (2008) 1.84
A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet (2011) 1.83
Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem (2006) 1.81
Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004) 1.79
Transcriptional neoteny in the human brain. Proc Natl Acad Sci U S A (2009) 1.78
Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Proteome Res (2008) 1.78
NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol (2008) 1.77
Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem (2006) 1.76
High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc (2010) 1.76
Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res (2008) 1.67
Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst (2003) 1.65
Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem (2006) 1.61
Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol (2011) 1.60
Recursive segment-wise peak alignment of biological (1)h NMR spectra for improved metabolic biomarker recovery. Anal Chem (2009) 1.59
Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies. Ann Surg (2014) 1.58
Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res (2009) 1.57
Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res (2006) 1.55
Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med (2014) 1.53
Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res (2010) 1.50
Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res (2010) 1.50
So what's the deal with metabonomics? Anal Chem (2003) 1.43
A metabonomic strategy for the detection of the metabolic effects of chamomile (Matricaria recutita L.) ingestion. J Agric Food Chem (2005) 1.42
Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol (2008) 1.42
Urinary metabolic phenotyping the slc26a6 (chloride-oxalate exchanger) null mouse model. J Proteome Res (2012) 1.41
The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics (2005) 1.41
Metabolic changes in schizophrenia and human brain evolution. Genome Biol (2008) 1.39
High-throughput 1H NMR-based metabolic analysis of human serum and urine for large-scale epidemiological studies: validation study. Int J Epidemiol (2008) 1.39
Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med (2006) 1.36
Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Med Genomics (2009) 1.31
Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol (2010) 1.31
Species variation in the fecal metabolome gives insight into differential gastrointestinal function. J Proteome Res (2007) 1.30
Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights (2010) 1.30
The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One (2008) 1.29
Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal Chem (2006) 1.29
Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chem Res Toxicol (2004) 1.26
Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J Proteome Res (2006) 1.25
Global metabolic responses of mice to Trypanosoma brucei brucei infection. Proc Natl Acad Sci U S A (2008) 1.24
Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile. Anal Biochem (2003) 1.24
Gut microbiome modulates the toxicity of hydrazine: a metabonomic study. Mol Biosyst (2009) 1.24
High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res (2008) 1.24
Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry (2008) 1.24
Phylometabonomic patterns of adaptation to high fat diet feeding in inbred mice. PLoS One (2008) 1.23
Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci U S A (2002) 1.22
Metabonomic investigations of aging and caloric restriction in a life-long dog study. J Proteome Res (2007) 1.21
Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur J Neurosci (2004) 1.18
Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res (2009) 1.18
Gene expression becomes heterogeneous with age. Curr Biol (2006) 1.18
Quantification of proteins using data-independent analysis (MSE) in simple andcomplex samples: a systematic evaluation. Proteomics (2011) 1.17
Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem Res Toxicol (2005) 1.17
Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation. J Proteome Res (2006) 1.16
Metabolic profiling and the metabolome-wide association study: significance level for biomarker identification. J Proteome Res (2010) 1.16
Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J Proteome Res (2010) 1.15
Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. Chem Res Toxicol (2002) 1.15
Clinical bioinformatics for complex disorders: a schizophrenia case study. BMC Bioinformatics (2009) 1.14
Variation in antibiotic-induced microbial recolonization impacts on the host metabolic phenotypes of rats. J Proteome Res (2011) 1.13
Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc (2012) 1.13
Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem (2014) 1.12
Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol (2007) 1.12
Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues. Anal Biochem (2003) 1.12
Diet composition and activity level of at risk and metabolically healthy obese American adults. Obesity (Silver Spring) (2013) 1.12
HILIC-UPLC-MS for exploratory urinary metabolic profiling in toxicological studies. Anal Chem (2010) 1.12
Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem (2005) 1.11
Metabotyping of long-lived mice using 1H NMR spectroscopy. J Proteome Res (2012) 1.11
Aberrant adiposity and ectopic lipid deposition characterize the adult phenotype of the preterm infant. Pediatr Res (2011) 1.11
The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal (2010) 1.10
Optimization of human plasma 1H NMR spectroscopic data processing for high-throughput metabolic phenotyping studies and detection of insulin resistance related to type 2 diabetes. Anal Chem (2008) 1.10